Species barrier of HIV-1 and its jumping by virus engineering

Reviews in Medical Virology

Volumn 18, Issue 4, 2008, Pages 261-275

  Nomaguchi, Masako ^a   Doi, Naoya ^a   Kamada, Kazuya ^a   Adachi, Akio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYCLOPHILIN A; TRIPARTITE MOTIF PROTEIN 5;

CELL LINE; CHIMERA; GENETIC ORGANIZATION; GENETIC TRAIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIROGENESIS;

ANIMALS; DISEASE MODELS, ANIMAL; HIV-1; HUMANS; IMMUNITY, NATURAL; RECOMBINATION, GENETIC; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 47649115344     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.576     Document Type: Review

References (137)

1. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992; 8(2): 119-134.
2. Uberla K, Stahl-Henning C, Bottiger D, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1995; 92(18): 8210-8214.
3. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9(1): 57-65.
4. Nishimura Y, Igarashi T, Donau OK, et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 2004; 101(33): 12324-12329.
5. Nishimura Y, Brown CR, Mattapallil JJ, et al. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA 2005; 102(22): 8000-8005.
6. Brown CR, Czapiga M, Kabat J, et al. Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol 2007; 81(11): 5594-5606.
7. Kanki PJ, McLane MF, King NW Jr, et al. Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science 1985; 228(4704): 1199-1201.
8. Daniel MD, Letvin NL, King NW, et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985; 228(4704): 1201-1204.
9. Letvin NL, Daniel MD, Sehgal PK, et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985; 230(4721): 71-73.
10. Naidu YM, Kestler HW III, Li Y, et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 1988; 62(12): 4691-4696.
11. Kestler H, Kodama T, Ringler D, et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 1990; 248(4959): 1109-1112.
12. Murphey-Corb M, Martin LN, Rangan SR, et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986; 321(6068): 435-137.
13. Fultz PN, McClure HM, Anderson DC, et al. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci USA 1986; 83(14): 5286-5290.
14. Hirsch VM, Olmsted RA, Murphey-Corb M, et al. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989; 339(6223): 389-392.
15. Fukasawa M, Miura T, Hasegawa A, et al. Sequence of simian immunodeficiency virus from African green monkey, a new member of the HTV/SIV group. Nature 1988; 333(6172): 457-461.
16. Daniel MD, Li Y, Naidu YM, et al. Simian immunodeficiency virus from African green monkeys. J Virol 1988; 62(11): 4123-4128.
17. Allan JS, Short M, Taylor ME, et al. Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J Virol 1991; 65(6): 2816-2818.
18. Tsujimoto H, Hasegawa A, Maki N, et al. Sequence of a novel simian immunodeficiency virus from a wild-caught African mandrill. Nature 1989; 341(6242): 539-541.
19. Souquiere S, Bibollet-Ruche F, Robertson DL, et al. Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol 2001; 75(15): 7086-7096.
20. Hirsch VM, Dapolite G, Johnson PR, et al. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol 1995; 69(2): 955-967.
21. Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol 1990; 8: 557-578.
22. Hirsch VM, Johnson PR. Pathogenic diversity of simian immunodeficiency viruses. Virus Res 1994; 32(2): 183-203.
23. Shibata R, Kawamura M, Sakai H, et al. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol 1991; 65(7): 3514-3520.
24. Hofmann W, Schubert D, LaBonte J, et al. Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 1999; 73(12): 10020-10028.
25. Cowan S, Hatziioannou T, Cunningham T, et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002; 99(18): 11914-11919.
26. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002; 99(18): 11920-11925.
27. Shibata R, Adachi A. SYV/HW recombinants and their use in studying biological properties. AIDS Res Hum Retroviruses 1992; 8(3): 403-109.
28. Luciw PA, Pratt-Lowe E, Shaw KE, et al. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995; 92(16): 7490-7494.
29. Joag SV, Li Z, Foresman L, et al. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996; 70(5): 3189-3197.
30. Reimann KA, Li JT, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996; 70(10): 6922-6928.
31. Igarashi T, Endo Y, Englund G, et al. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci USA 1999; 96(24): 14049-14054.
32. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5(2): 204-210.
33. Nishimura Y, Igarashi T, Haigwood NL, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 2003; 100(25): 15131-15136.
34. Ambrose Z, Boltz V, Palmer S, et al. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 2004; 78(24): 13553-13561.
35. Amara R, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292(5514): 69-74.
36. Matano T, Kano M, Nakamura H, et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001; 75(23): 11891-11896.
37. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415(6869): 331-335.
38. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79(24): 15547-15555.
39. Mattapallil JJ, Douek DC, Buckler-White A, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006; 203(6): 1533-1541.
40. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312(5779): 1530-1533.
41. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280(5362): 427-431.
42. Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434(7037): 1093-1097.
43. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434(7037): 1148-1152.
44. Harouse JM, Gettie A, Tan RC, et al. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999; 284(5415): 816-819.
45. Tan RC, Harouse JM, Gettie A, et al. In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J Med Primatol 1999; 28(4-5): 164-168.
46. Song RJ, Chenine AL, Rasmussen RA, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006; 80(17): 8729-8738.
47. Misumi S, Nakayama D, Kusaba M, et al. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. J Immunol 2006; 176(1): 463-471.
48. Cristillo AD, Lisziewicz J, He L, et al. HIV-1 prophylactic vaccine comprised of topical Derma Vir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007; 366(1): 197-211.
49. Ho SH, Shek L, Gettie A, et al. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol 2005; 79(19): 12296-12303.
50. Tsai L, Trunova N, Gettie A, et al. Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans. Virology 2007; 362(1): 207-216.
51. Dorfman T, Göttlinger HG. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. J Virol 1996; 70(9): 5751-5757.
52. Shibata R, Sakai H, Kawamura M, et al. Early replication block of human immunodeficiency virus type 1 in monkey cells. J Gen Virol 1995; 76(Pt 11): 2723-2730.
53. Towers G, Bock M, Matin S, et al. A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci USA 2000; 97(22): 12295-12299.
54. Towers G, Collins M, Takeuchi Y. Abrogation of Ref1 retrovirus restriction in human cells. J Virol 2002; 76(5): 2548-2550.
55. Hatziioannou T, Cowan S, Goff SP, et al. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 2003; 22(3): 385-394.
56. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427(6977): 848-853.
57. Yap MW, Nisole S, Lynch C, et al. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004; 101(29): 10786-10791.
58. Perron MJ, Stremlau M, Song B, et al. TRIM5alpha mediates the postentry block to N-tiopic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 2004; 101(32): 11827-11832.
59. Song B, Javanbakht H, Perron M, et al. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 2005; 79(7): 3930-3937.
60. Borden KL, Lally JM, Martin SR, et al. Novel topology of a zinc-binding domain from a protein involved in regulating early Xenopus development. EMBO J 1995; 14(23): 5947-5956.
61. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J 2001; 20(9): 2140-2151.
62. Massiah MA, Simmons BN, Short KM, et al. Solution structure of the RBCC/TRIM B-box1 domain of human MID1: B-box with a RING. J Mol Biol 2006; 358(2): 532-545.
63. Massiah MA, Matts JA, Short KM, et al. Solution structure of the MID1 B-box2 CHC(D/C)C(2)H(2) zinc-binding domain: insights into an evolutionarily conserved RING fold. J Mol Biol 2007; 369(1): 1-10.
64. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005; 15(1): 73-78.
65. Stremlau M, Perron M, Welikala S, et al. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79(5): 3139-3145.
66. Nakayama EE, Miyoshi H, Nagai Y, et al. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5-alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 2005; 79(14): 8870-8877.
67. Perez-Caballero D, Hatziioannou T, Yang A, et al. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 2005; 79(14): 8969-8978.
68. Perron MJ, Stremlau M, Sodroski J. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. J Virol 2006; 80(11): 5631-5636.
69. Stremlau M, Perron M, Lee M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 2006; 103(14): 5514-5519.
70. Perron MJ, Stremlau M, Lee M, et al. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 2007; 81(5): 2138-2148.
71. Forshey BM, von Schwedler U, Sundquist WI, et al. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002; 76(11): 5667-5677.
72. Wu X, Anderson JL, Campbell EM, et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 2006; 103(19): 7465-7470.
73. Anderson JL, Campbell EM, Wu X, et al. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 2006; 80(19): 9754-9760.
74. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 2007; 81(3): 1054-1061.
75. Luban J, Bossolt KL, Franke EK, et al. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73(6): 1067-1078.
76. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994; 372(6504): 359-362.
77. Thali M, Bukovsky A, Kondo E, et al. Functional association of cyclophilin A with HIV-1 virions. Nature 1994; 372(6504): 363-365.
78. Hatziioannou T, Perez-Caballero D, Cowan S, et al. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 2005; 79(1): 176-183.
79. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004; 78(23): 12800-12808.
80. Sayah DM, Sokolskaja E, Berthoux L, et al. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004; 430(6999): 569-573.
81. Berthoux L, Sebastian S, Sokolskaja E, et al. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA 2005; 102(41): 14849-14853.
82. Keckesova Z, Ylinen L, Towers GJ. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006; 80(10): 4683-4690.
83. Stremlau M, Song B, Javanbakht H, et al. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 2006; 351(1): 112-120.
84. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006; 80(6): 2855-2862.
85. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007; 4: 40.
86. Sodroski J, Goh WC, Rosen C, et al. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 1986; 231(4745): 1549-1553.
87. Strebel K, Daugherty D, Clouse K, et al. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987; 328(6132): 728-730.
88. Fisher AG, Ensoli B, Ivanoff L, et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987; 237(4817): 888-893.
89. Sheehy AM, Gaddis NC, Choi JD, et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898): 646-650.
90. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004; 4(11): 868-877.
91. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 2007; 32(3): 118-128.
92. Bishop KN, Holmes RK, Sheehy AM, et al. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14(15): 1392-1396.
93. Doehle BP, Schäfer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005; 339(2): 281-288.
94. Rose KM, Marin M, Kozak SL, et al. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum Retroviruses 2005; 21(7): 611-619.
95. Dang Y, Wang X, Esselman WJ, et al. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 2006; 80(21): 10522-10533.
96. Liddament MT, Brown WL, Schumacher AJ, et al. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004; 14(15): 1385-1391.
97. Wiegand HL, Doehle BP, Bogerd HP, et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004; 23(12): 2451-2458.
98. Zheng YH, Irwin D, Kurosu T, et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004; 78(11): 6073-6076.
99. Liu B, Sarkis PT, Luo K, et al. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 2005; 79(15): 9579-9587.
100. Holmes RK, Koning FA, Bishop KN, et al. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007; 282(4): 2587-2595.
101. Lecossier D, Bouchonnet F, Clavel F, et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300(5622): 1112.
102. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113(6): 803-809. Erratum in: Cell 2004; 116(4): 629.
103. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424(6944): 94-98.
104. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424(6944): 99-103.
105. Mariani R, Chen D, Schröfelbauer B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114(1): 21-31.
106. Newman EN, Holmes RK, Craig HM, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15(2): 166-170.
107. Shindo K, Takaori-Kondo A, Kobayashi M, et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 2003; 278(45): 44412-44416.
108. Chiu YL, Soros VB, Kreisberg JF, et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435(7038): 108-114.
109. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80(17): 8450-8458.
110. Iwatani Y, Chan DS, Wang F, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 2007; 35(21): 7096-7108.
111. Marin M, Rose KM, Kozak SL, et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9(11): 1398-1403.
112. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9(11): 1404-1407.
113. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Nature 2003; 302(5647): 1056-1060.
114. Mehle A, Strack B, Ancuta P, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279(9): 7792-7798.
115. Stopak K, de Noronha C, Yonemoto W, et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12(3): 591-601.
116. Kao S, Khan MA, Miyagi E, et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77(21): 11398-11407.
117. Santa-Marta M, da Silva FA, Fonseca AM, et al. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem 2005; 280(10): 8765-8775.
118. Cullen BR. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006; 80(3): 1067-1076.
119. Tian C, Yu X, Zhang W, et al. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80(6): 3112-3115.
120. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81(15): 8201-8210.
121. Mehle A, Wilson H, Zhang C, et al. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007; 81(23): 13235-13241.
122. Chen ZW, Kou ZC, Lekutis C, et al. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med 1995; 182(1): 21-31.
123. Mascola JR, Lewis MG, VanCott TC, et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol 2003; 77(19): 10348-10356.
124. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76(5): 2123-2130.
125. Fujita M, Yoshida A, Miyaura M, et al. Cyclophilin A-independent replication of a human immunodeficiency virus type 1 isolate carrying a small portion of the simian immunodeficiency virus SIV(MAC) gag capsid region. J Virol 2001; 75(21): 10527-10531.
126. Kamada K, Yoshida A, Khamsri B, et al. Construction of gag-chimeric viruses between HIV-1 and SIVmac that are capable of productive multi-cycle infection. Microbes Infect 2006; 8(4): 1075-1081.
127. Akari H, Fukumori T, Iida S, et al. Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86. Biochem Biophys Res Commun 1999; 263(2): 352-356.
128. Kamada K, Igarashi T, Martin MA, et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci USA 2006; 103(45): 16959-16964.
129. Sakurai A, Jere A, Yoshida A, et al. Functional analysis of HIV-1 vif genes derived from Japanese long-term nonprogressors and progressors for AIDS. Microbes Infect 2004; 6(9): 799-805.
130. Willey RL, Smith DH, Lasky LA, et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988; 62(1): 139-147.
131. Freed EO, Martin MA. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996; 70(1): 341-351.
132. Hatziioannou T, Princiotta M, Piatak M Jr, et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 2006; 314(5796): 95.
133. Schröfelbauer B, Senger T, Manning G, et al. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 2006; 80(12): 5984-5991.
134. Igarashi T, Iyengar R, Byrum RA, et al. Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol 2007; 81(20): 11549-11552.
135. Chen P, Hübner W, Spinelli MA, et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007; 81(22): 12582-12595.
136. Hübner W, Chen P, Del Portillo A, et al. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol 2007; 81(22): 12596-12607.
137. Desrosiers RC. Nonhuman lentiviruses. In Fields Virology, 5th edn. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds). Lippincott Williams & Wilkins: Philadelphia, PA, 2007; 2215-2243.